Schrodinger’s Pricing: Conceptual and Practical Challenges of Conditional PAS in the NICE Technology Appraisal of Lorlatinib for Untreated ALK-Positive Advanced Non-small-cell Lung Cancer (Review of TA1103): An External Assessment Group Perspective
本文未提供摘要，请点击“查看全文”查看完整内容。